New Jersey residents have long faced one of the most frustrating realities in modern healthcare: the price of prescription medications continues to climb, often faster than wages, insurance coverage, or household budgets can keep up. Now, a newly activated state panel is stepping directly into the center of that challenge. The New Jersey Drug Affordability Council has begun a sweeping investigation into the intricate network of companies, policies, and financial incentives that ultimately determine what residents pay at the pharmacy counter.

Created under New Jersey’s Prescription Drug Affordability and Transparency Law, which fully took effect on January 1, 2025, the council represents one of the state’s most ambitious efforts to understand—and potentially reshape—the economics of prescription drug pricing. The panel is now gathering public input, analyzing industry practices, and examining the complicated pharmaceutical supply chain with the goal of recommending legislative reforms that could significantly reduce costs for New Jersey patients. (Frier Levitt)

For residents across the Garden State—from seniors managing chronic conditions to families dealing with asthma, diabetes, and life-saving medications—the stakes are enormous.

The work underway has the potential to reshape how prescription drugs are priced, negotiated, and delivered in New Jersey’s healthcare system.

Why New Jersey Created the Drug Affordability Council

The creation of the council is rooted in a growing recognition among policymakers that the traditional prescription drug market is anything but straightforward. A patient paying for medication at a pharmacy may only see the final price on the receipt, but that number is the result of negotiations and transactions involving manufacturers, insurance carriers, wholesalers, pharmacy chains, and pharmacy benefit managers.

The state established the council as an independent advisory body tasked with studying the entire pharmaceutical distribution and payment system operating within New Jersey. Its primary mission is to identify the factors driving rising costs and develop policy recommendations that protect residents, healthcare providers, insurers, and public programs from escalating drug prices. (Justia Law)

The panel is expected to review industry data, pricing trends, and the broader economics of the pharmaceutical marketplace while delivering regular recommendations to the governor and the state legislature.

The ultimate goal is clear: make prescription medications more affordable without compromising access or innovation.

The “Dizzying” Drug Supply Chain Under Investigation

One of the council’s earliest priorities is unpacking the complexity of the pharmaceutical supply chain itself.

For many residents, the price of a medication appears to be determined solely by the drug manufacturer. In reality, the path from pharmaceutical development to a pharmacy shelf involves a series of financial relationships that can dramatically influence costs.

The council is now closely examining the roles played by wholesalers, insurers, pharmacies, and especially pharmacy benefit managers—often referred to as PBMs.

These middlemen occupy a powerful position within the healthcare system, negotiating pricing and rebates between drug manufacturers and insurance companies.

While PBMs were originally intended to help control costs, critics argue that some of their practices may actually contribute to higher prices.

Pharmacy Benefit Managers and the Question of “Spread Pricing”

One of the most closely scrutinized practices now under investigation is spread pricing.

Spread pricing occurs when a pharmacy benefit manager charges an insurance plan more for a medication than it reimburses the pharmacy that actually dispenses the drug. The difference between those two amounts—the “spread”—can become a source of revenue for the PBM.

State officials are analyzing whether this system is contributing to higher drug costs for consumers, insurers, and government programs.

The council is also examining how rebates negotiated between PBMs and drug manufacturers are handled. In many cases, drug companies offer significant rebates to insurers or PBMs in exchange for favorable placement on insurance formularies.

But critics argue that those rebates are not always passed along to patients.

Instead, they may be absorbed within the system, leaving consumers paying inflated prices based on a drug’s list price rather than its discounted value.

The Role of Rebates and Rising List Prices

Another major area of focus for the council involves the relationship between rebates and drug list prices.

In theory, rebates are intended to reduce costs for insurers and patients.

In practice, however, some policymakers believe they may create unintended consequences.

Manufacturers sometimes raise the list price of medications to offset the rebates demanded by insurers and pharmacy benefit managers. The higher list price allows companies to maintain profitability while still providing rebates.

But patients who must pay coinsurance based on the list price—rather than the discounted amount—can end up paying significantly more.

The council’s work aims to determine whether the current rebate-driven model is functioning as intended or whether it is inadvertently driving prices higher across the system.

Patent Strategies and the Battle Over Generic Competition

Generic competition has historically been one of the most powerful forces for lowering drug prices.

Once a drug’s patent expires and generic manufacturers enter the market, prices typically drop dramatically.

However, the council is also examining strategies that brand-name manufacturers sometimes use to extend their market exclusivity.

These strategies can include complex patent portfolios known as “patent thickets,” where multiple overlapping patents are filed around a single drug. Critics argue that such tactics can delay generic competitors for years, allowing manufacturers to maintain higher prices long after the original patent should have expired.

By studying these practices, New Jersey policymakers hope to identify ways to accelerate the arrival of lower-cost alternatives.

The Possibility of Upper Payment Limits

Perhaps the most consequential power tied to the broader prescription drug affordability framework is the concept of Upper Payment Limits.

Under the state’s legislative framework, policymakers may eventually consider establishing caps on the amount that certain programs or insurers can pay for specific high-cost drugs.

These limits would apply to medications identified as creating significant affordability challenges within the healthcare system.

Before such measures can be implemented, however, extensive analysis is required. The council’s research and recommendations will help determine whether price caps are a viable tool and how they might be structured without disrupting access to necessary medications. (New Jersey Legislature)

The issue is complex, and any decision to impose payment limits would likely require legislative approval.

Transparency Laws Already Delivering Immediate Relief

While the council works toward long-term reforms, several provisions of New Jersey’s drug affordability legislation are already delivering tangible benefits to residents.

Among the most immediate changes are caps on certain out-of-pocket costs.

For many patients enrolled in state-regulated insurance plans, insulin costs are now capped at $35 per month. Epinephrine auto-injectors are capped at $50, and asthma inhalers are also limited to $50 out of pocket.

These caps are designed to ensure that essential medications remain accessible to patients who depend on them for life-saving treatment.

At the same time, new transparency rules require pharmaceutical manufacturers to report significant price increases to the state. This data helps regulators and policymakers track trends in drug pricing and identify medications that may require closer review.

Manufacturers, insurers, wholesalers, and pharmacy benefit managers are now required to report detailed pricing information, creating an unprecedented level of visibility into how prescription drug prices evolve across the supply chain. (New Jersey Legislature)

A Data-Driven Approach to Drug Pricing Reform

One of the most important aspects of the new system is its reliance on comprehensive data.

Every year, the state’s Division of Consumer Affairs collects and analyzes information from manufacturers, insurers, PBMs, and wholesalers regarding pricing trends, sales volumes, and revenue changes.

These reports are intended to identify the underlying drivers of prescription drug costs and highlight areas where policy changes may be necessary.

The Drug Affordability Council uses that information as the foundation for its recommendations.

By combining industry data with expert analysis and public input, the council aims to develop policy solutions grounded in real-world evidence rather than speculation.

What This Means for New Jersey Residents

For patients across New Jersey, the council’s work represents a significant shift toward greater accountability within the pharmaceutical marketplace.

Prescription drug affordability has become one of the most pressing healthcare issues nationwide, affecting seniors, families, and patients managing chronic diseases.

New Jersey’s approach recognizes that the problem cannot be solved by targeting a single actor within the system.

Instead, the council’s mandate is to examine the entire ecosystem—from manufacturers and wholesalers to insurers and pharmacy benefit managers—to determine how each component contributes to the final price patients pay.

The recommendations emerging from this process could ultimately shape new legislation, regulatory reforms, and pricing strategies designed to bring relief to consumers.

A New Chapter in New Jersey’s Health Policy Landscape

The activation of the Drug Affordability Council marks a new phase in New Jersey’s broader effort to strengthen healthcare affordability across the state.

As the council gathers testimony, reviews industry data, and studies pricing practices, its work will likely become a central focus in future healthcare policy debates.

For residents following developments in health policy, prescription drug affordability, and consumer protections, the issue will remain one of the most important areas to watch in the months ahead.

Explore more health coverage and updates shaping healthcare access across the state in the Health & Wellness section at Explore New Jersey, where we continue tracking the policies, programs, and innovations shaping the future of health across the Garden State.